Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway
Open Access
- 22 January 2019
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 1-15
Abstract
The long noncoding RNA (lncRNA) OTUD6B antisense RNA 1 (OTUD6B-AS1) is oriented in an antisense direction to the protein-coding gene OTUD6B on the opposite DNA strand. TCGA database data show that the expression of the lncRNA OTUD6B-AS1 is downregulated and that OTUD6B-AS1 acts as an antioncogene in a variety of tumors. However, the expression and biological functions of the lncRNA OTUD6B-AS1 are still unknown in tumors, including clear cell renal cell carcinoma (ccRCC). The expression level of OTUD6B-AS1 was measured in 75 paired human ccRCC tissue and corresponding adjacent normal renal tissue samples. The correlations between the OTUD6B-AS1 expression level and clinicopathological features were evaluated using the chi-square test. The effects of OTUD6B-AS1 on ccRCC cells were determined via MTT assay, clone formation assay, transwell assay, and flow cytometry. Furthermore, the impact of OTUD6B-AS1 overexpression on the activation of the Wnt/β-catenin signaling pathway was investigated. Finally, ACHN cells with OTUD6B-AS1 overexpression were subcutaneously injected into nude mice to evaluate the influence of OTUD6B-AS1 on tumor growth in vivo. In this study, we found that the expression of the lncRNA OTUD6B-AS1 was downregulated in ccRCC tissue samples and that patients with low OTUD6B-AS1 expression had shorter overall survival than patients with high OTUD6B-AS1 expression, which showed that the different expression level of OTUD6B-AS1 indirectly correlated with survival of patients. Lentivirus-mediated OTUD6B-AS1 overexpression significantly decreased the proliferation of ccRCC cells and promoted the apoptosis of the cells. Furthermore, OTUD6B-AS1 overexpression partly inhibited cell migration and invasion. The overexpression of OTUD6B-AS1 decreased the activity of the Wnt/β-catenin pathway and suppressed the expression of epithelial-to-mesenchymal transition (EMT)-related proteins (E-cadherin, N-cadherin and Snail) in ccRCC cells. In addition, compared with the parental ACHN cells, OTUD6B-AS1-overexpressing ACHN cells injected into nude mice exhibited decreased tumor growth in vivo. Taken together, our findings present a road map for targeting the newly identified lncRNA OTUD6B-AS1 to suppress ccRCC progression in cell lines, and these results elucidate a novel potential therapeutic target for ccRCC treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81171996, 81272289, 8187101951)
- The First Affiliated Hospital of Harbin Medical University Science Foundation (2015B011)
This publication has 39 references indexed in Scilit:
- β-Catenin Activation in a Novel Liver Progenitor Cell Type Is Sufficient to Cause Hepatocellular Carcinoma and HepatoblastomaCancer Research, 2014
- Long Noncoding RNA in Prostate, Bladder, and Kidney CancerEuropean Urology, 2014
- Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancerMolecular Cancer, 2014
- MicroRNA‐344 inhibits 3T3‐L1 cell differentiation via targeting GSK3β of Wnt/β‐catenin signaling pathwayFEBS Letters, 2013
- LncRNA loc285194 is a p53-regulated tumor suppressorNucleic Acids Research, 2013
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trialsBJU International, 2011
- Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human gliomaJournal of Translational Medicine, 2011
- Knockdown of β-Catenin Through shRNA Cause a Reversal of EMT and Metastatic Phenotypes Induced by HIF-1αCancer Investigation, 2011
- LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanismsOncogene, 2011